TapewireFind a company

person · Reporting owner

Mensinger Mike

Disclosed activity across 1 company

Tapewire entity
2351
SEC CIK
0002048500

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Beta Bionics, Inc.BBNX · Entity 2350Chief Product OfficerSeptember 16, 2026September 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Beta Bionics, Inc.

Report date September 16, 2026 · Filed September 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect177,390 Reported balance After 2026-09-16 transaction · row 1
1 source row

Row 1 · 2026-09-16 · Sale · Disposed 2,650 · Balance 177,390

F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 16, 2026 Filed Sep 17, 2026 20:15 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 2,650 $22.00 $58,300.00
Disclosure

SEC source: 0002048500-26-000013 · form4-09172026_040904.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,390

F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

Read SEC document
September 02, 2026 Filed Sep 3, 2026 22:15 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 4,375 $19.11 $83,619.81
Disclosure

SEC source: 0002048500-26-000012 · form4-09032026_060904.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,040

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
June 02, 2026 Filed Jun 3, 2026 22:13 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 4,378 $12.61 $55,193.88
Disclosure

SEC source: 0002048500-26-000009 · form4-06032026_100646.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,415

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 23:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 1,064 $12.36 $13,152.74
Disclosure

SEC source: 0002048500-26-000004 · form4-03032026_060306.xml · nonDerivative · entry 2

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,793

F2 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 58,749 $0.00 Strike: $12.63 $0.00
Disclosure

SEC source: 0002048500-26-000004 · form4-03032026_060306.xml · derivative · entry 3

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,749

Underlying: Common Stock · 58,749 shares

Expires 2036-02-26

F4 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 23:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantCommon Stock 109,105 $0.00 $0.00
Disclosure

SEC source: 0002048500-26-000004 · form4-03032026_060306.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,857

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Read SEC document
February 27, 2026 Filed Mar 13, 2026 20:15 UTC Amendment Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 91,520 $0.00 Strike: $12.63 $0.00
Disclosure

SEC source: 0002048500-26-000006 · form4a-03132026_040314.xml · derivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,520

Underlying: Common Stock · 91,520 shares

Expires 2036-02-26

F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Read SEC document
January 06, 2026 Filed Jan 7, 2026 21:16 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 2,200 $30.10 $66,221.10
Disclosure

SEC source: 0002048500-26-000003 · form4-01072026_090132.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,752

F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

F2 · price: The weighted average sale price for the transaction reported was $30.1005 and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 23:05 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 600 $30.20 $18,118.14
Disclosure

SEC source: 0002048500-26-000002 · form4-01052026_110121.xml · nonDerivative · entry 2

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,952

F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

F3 · price: The weighted average sale price for the transaction reported was $30.1969 and the range of prices were between $30.10 and $30.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 23:05 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 7,200 $29.56 $212,832.00
Disclosure

SEC source: 0002048500-26-000002 · form4-01052026_110121.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,552

F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.

F2 · price: The weighted average sale price for the transaction reported was $29.56 and the range of prices were between $29.05 and $30.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
December 02, 2025 Filed Dec 4, 2025 21:20 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 1,063 $29.34 $31,184.06
Disclosure

SEC source: 0002048500-25-000004 · form4-12042025_041205.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,752

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Read SEC document
September 02, 2025 Filed Sep 4, 2025 22:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 1,089 $18.86 $20,542.02
Disclosure

SEC source: 0001415889-25-023744 · form4-09042025_060906.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,815

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 23:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 101 $18.69 $1,887.79
Disclosure

SEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 3

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,904

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F4 · price: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 23:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 708 $18.15 $12,849.42
Disclosure

SEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 2

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,005

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 23:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 306 $17.03 $5,210.57
Disclosure

SEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,713

F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
February 27, 2025 Filed Mar 3, 2025 22:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 52,000 $0.00 Strike: $19.91 $0.00
Disclosure

SEC source: 0001415889-25-006232 · form4-03032025_050306.xml · derivative · entry 2

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2035-02-26

F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from February 27, 2025.

Read SEC document
February 27, 2025 Filed Mar 3, 2025 22:45 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantCommon Stock 35,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-006232 · form4-03032025_050306.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,019

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 110,278 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 9

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,278

Underlying: Common Stock · 110,278 shares

Expires 2025-01-28

F7 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.

F6 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 236,553 $0.00 Strike: $5.10 $0.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 8

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,553

Underlying: Common Stock · 236,553 shares

Expires 2033-09-13

F5 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.

F6 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 OtherClass B Common Stock Warrant (right to buy) · Derivative 10,575 $0.00 Strike: $0.02 $0.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 7

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,575 shares

Expires 2033-08-27

F4 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 ConversionClass B Common Stock Warrant (right to buy) · Derivative 10,575 $0.00 Strike: $0.02 $0.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 6

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,575

Underlying: Common Stock · 10,575 shares

Expires 2033-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 ConversionSeries D Preferred Stock · Derivative 15,107 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 5

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,107 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

F1 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 PurchaseCommon Stock 33,350 $17.00 $566,950.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 4

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,019

F3 · kind: The shares were purchased in the Issuer's initial public offering.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 SaleCommon Stock 13 $17.00 $221.00
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 3

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,669

F2 · kind: On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 OtherCommon Stock 10,575 $0.02 $211.50
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 2

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,682

Read SEC document
January 31, 2025 Filed Feb 4, 2025 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 ConversionCommon Stock 15,107 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

Read SEC document
January 29, 2025 Filed Jan 31, 2025 21:32 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantEmployee Stock Option (right to buy) · Derivative 110,278 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001415889-25-002481 · form4-01312025_090141.xml · derivative · entry 1

Mensinger Mike · CIK 0002048500 · Chief Product Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,278

Underlying: Class B Common Stock · 110,278 shares

Expires 2035-01-28

F1 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.

F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.